581 Matching-adjusted indirect treatment comparison of tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy and nivolumab + ipilimumab + chemotherapy for first-line metastatic NSCLC

Abstract

BackgroundTremelimumab plus durvalumab and chemotherapy (T+D+CT), for first-line treatment of metastatic NSCLC, has been evaluated vs CT in a randomized phase III trial, POSEIDON (NCT03164616). In the absence of head-to-head...